Chimeron Bio
Business Services · Pennsylvania, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
601 Walnut St Ste 715, Philadelphia, Pen...Phone Number
(703) 993-8723Website
www.chimeron.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Chimeron Bio
Chimeron Bio is at the forefront of genetic medicine, specializing in pioneering MultiPlex In-Vivo CAR-T therapy that enables complex, multi-gene therapeutic constructs to be delivered directly in vivo. Their innovative approach aims to revolutionize patient access to advanced cell therapies, making them as accessible as traditional biologics. The company focuses on therapeutic applications across various fields, including oncology and autoimmunity. With a commitment to breakthrough science and transformative impact, Chimeron Bio is redefining the possibilities in cell therapy.Explore more
Chimeron Bio Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Chimeron Bio your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Chimeron Bio, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Chimeron Bio had a recent Job posting/layoffs
Check out if Chimeron Bio is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at Chimeron Bio
Funding: Get notified immidiatlly once Chimeron Bio has new funding data
Check if Chimeron Bio has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Chimeron Bio launches new products
Earning: See what the market has to say on Chimeron Bio recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Reach out to Masked Content who joined Chimeron Bio as Masked Content
Find 3 more new buyers
Compare Similar Companies to Chimeron Bio
Compare insights from companies similar to Chimeron Bio, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Chimeron Bio is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Chimeron Bio is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Chimeron Bio.
Chimeron Bio Tech Stack
A closer look at the technologies used by Chimeron Bio
Most Recent Scoops
Executive Move
Board of Directors
New Hire
Executive Move
Facilities Relocation / Expansion
Chimeron Bio is planning to move its offices in August 2022. The move will impact employees at their existing office located at 3675 Market St., Philadelphia, PA.
Facilities Relocation/Expansion
Facilities Relocation / Expansion
Facilities Relocation/Expansion
Chimeron Bio News & Media
Chimeron Bio Appoints Antonin (Tony) de Fougerolles to its Board of Directors
Chimeron Bio, an RNA company developing self-amplifying RNA (saRNA) vaccines and therapeutics designed on its proprietary ChaESAR™ RNA delivery platfoChimeron Bio Appoints Antonin (Tony) de Fougerolles to its Board of Directors
PHILADELPHIA--(BUSINESS WIRE)--Chimeron Bio, an RNA company developing self-amplifying RNA (saRNA) vaccines and therapeutics designed on its proprietary ChaESAR™ RNA delivery platform, announced today that Antonin (Tony) de Fougerolles had been appointed as the newest member of its Board of Directors. As the former founding CSO of Moderna, Tony is a pioneer in RNA technology with a long track record of successfully scaling biotechnology organizations from the start-up stage. “I can’t adequatelyChimeron Bio Welcomes Kevin Heyeck as New CEO
PHILADELPHIA--(BUSINESS WIRE)--Chimeron Bio, an RNA company developing self-amplifying RNA (saRNA) vaccines and therapeutics designed on its proprietary ChaESAR™ RNA delivery platform, announced today that Kevin Heyeck had been named Chief Executive Officer. Kevin comes to Chimeron with a long and successful track record of executive and entrepreneurial experience in life sciences. Kevin began his career at Harvard University’s Office of Technology Licensing, then went on to lead corporate andChimeron Bio Enters Into Manufacturing Agreement With FUJIFILM Diosynth Biotechnologies to Advance its RNA Oncology Candidates
PHILADELPHIA & COLLEGE STATION, Texas--(BUSINESS WIRE)--Chimeron Bio, an RNA company developing self-amplifying RNA (saRNA) vaccines and therapeutics designed on its proprietary ChaESAR™ RNA delivery platform, today announced it has entered into a manufacturing agreement with FUJIFILM Diosynth Biotechnologies (FDB), a leading Contract Development and Manufacturing Organization (CDMO) with experience in the development and manufacture of recombinant biopharmaceuticals and viral gene therapies, t
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Frequently Asked Questions Regarding Chimeron Bio
Sign Up For FreeTo access detailed company insights
Chimeron Bio is at the forefront of genetic medicine, specializing in pioneering MultiPlex In-Vivo CAR-T therapy that enables complex, multi-gene therapeutic constructs to be delivered directly in vivo. Their innovative approach aims to revolutionize patient access to advanced cell therapies, making them as accessible as traditional biologics. The... Read More
